2022
DOI: 10.1016/j.drup.2022.100806
|View full text |Cite
|
Sign up to set email alerts
|

Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
31
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 56 publications
(38 citation statements)
references
References 267 publications
0
31
0
Order By: Relevance
“…The tumor microenvironment includes a variety of complex cell components, such as immune cells, stromal cells, and tumor cells ( Shi et al, 2022 ; Van den Bossche et al, 2022 ). The difference in their composition and expression is one of the main reasons for tumor heterogeneity ( Srinivasan et al, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…The tumor microenvironment includes a variety of complex cell components, such as immune cells, stromal cells, and tumor cells ( Shi et al, 2022 ; Van den Bossche et al, 2022 ). The difference in their composition and expression is one of the main reasons for tumor heterogeneity ( Srinivasan et al, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…The current release of includes 23 cancer transcriptomics gene signatures, which were selected mainly due to our interest in the tumor microenvironment biology and its possible influence on response to treatment in head and neck cancer patients ( Van den Bossche et al , 2022 ). The function can be used to retrieve IDs, associated keywords, DOIs for the original publication and a brief description for each signature (see also Supplementary Table S1 ).…”
Section: Features and Methodsmentioning
confidence: 99%
“…Currently, the TNM Classification of Malignant Tumors (TNM) stage of disease is the crucial prognostic factor for the overall survival of HNSCC patients ( Specenier and Vermorken, 2018 ). However, the survival rate of HNSCC patients has not significantly improved, emphasizing the need for reliable predictive biomarkers ( Biomarkers Definitions Working Group, 2001 ) and new treatment strategies ( Takes et al, 2012 ; Van den Bossche et al, 2022 ). In addition, several studies have revealed that gene mutations and molecular pathological subtypes considerably impact the prognosis of HNSCC patients.…”
Section: Introductionmentioning
confidence: 99%